Comparative Immunogenicities of Chikungunya Vaccines Prepared in Avian and Mammalian Tissues

Harrison, V. R.; Binn, Leonard N.; Re, Randall

doi:10.4269/ajtmh.1967.16.786

Cited by 41 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an earlier study, sera from CHIKV-vaccinated mice and monkeys cross-neutralised different CHIKV strains from Africa, Asia, and India. 21 Cross-neutralisation may limit the impact of a new CHIKV genotype being introduced into a population already immunised by natural infection or vaccination. Studies of potential vaccines 22,23 should confirm this by testing efficacy against all CHIKV genotypes.…”

Section: Discussionmentioning

confidence: 99%

Chikungunya virus of Asian and Central/East African genotypes in Malaysia

Sam

Chan

et al. 2009

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Chikungunya virus of Asian and Central/East African genotypes in Malaysia

Sam

Chan

et al. 2009

Journal of Clinical Virology

View full text Add to dashboard Cite

“…[12][13][14][15] Individual strains of CHIK are closely related antigenically, 9,16,17 and infection with one CHIK strain leads to protection against all strains. 18 Reciprocal cross-protection after infection with other alphaviruses occurs in animal models, 19,20 although it is unclear if similar cross protection occurs in humans sequentially exposed to natural infection or live alphavirus vaccines. 21 An isolate from a patient in Thailand, CHIK strain 15561, was used to develop a small lot of vaccine first passaged in green monkey kidney (GMK) cells and then formalin-inactivated before administration to 16 volunteers.…”

Section: Introductionmentioning

confidence: 99%

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

Edelman¹,

Tacket²,

Wasserman³

et al. 2000

The American Journal of Tropical Medicine and Hygiene

283

229

View full text Add to dashboard Cite

Abstract. We conducted a phase II, randomized, double-blind, placebo-controlled, safety and immunogenicity study of a serially passaged, plaque-purified live chikungunya (CHIK) vaccine in 73 healthy adult volunteers. Fiftynine volunteers were immunized one time subcutaneously with the CHIK vaccine and 14 were immunized with placebo (tissue culture fluid). Vaccinees were clinically evaluated intensively for one month, and had repeated blood draws for serological assays (50% plaque-reduction neutralization test) for one year. Except for transient arthralgia in five CHIK vaccinees, the number and severity of local and systemic reactions and abnormal laboratory tests after immunization were similar in CHIK vaccinees and placebo recipients. Fifty-seven (98%) of 58 evaluable CHIK vaccinees developed CHIK neutralizing antibody by day 28, and 85% of vaccinees remained seropositive at one year after immunization. No placebo recipients seroconverted. This promising live vaccine was safe, produced well-tolerated side effects, and was highly immunogenic.

show abstract

“…Due to the easiness in preparation, the first developed vaccines were formulations of whole-virus grew on cells and inactivated either by formalin or tween-ether (Eckels et al, 1970;Harrison et al, 1967Harrison et al, , 1971White et al, 1972). Further vaccines are focused on attenuated strains of CHIK obtained after serial passages in cells cultures (Edelman et al, 2000;Levitt et al, 1986).…”

Section: Preventionmentioning

confidence: 99%